Experimental vaccine used in Ebola exposure case
BERLIN -- It was a nightmare scenario: A scientist accidentally pricked her finger with a needle used to inject the deadly Ebola virus into lab mice. Within hours, members of a tightly bound, yet far-flung community of virologists, biologists and others were tensely gathered in a trans-Atlantic telephone conference trying to map out a way to save her life.
Less than 24 hours later, an experimental vaccine — never before tried on humans — was on its way to Germany from a lab in Canada.
And within 48 hours of the March 12 accident, the at-risk scientist, a 45-year-old woman whose identity has not been revealed, was injected with the vaccine.
So far, so good. If the woman is still healthy by Thursday, she can consider herself safe.
Ebola hemorrhagic fever, seen mostly only in Africa, is one of the world's most feared diseases. It begins with flu-like symptoms, followed by bloody diarrhea and vomiting. Days later, some victims begin bleeding through the nose, mouth and eyes. Depending on the strain of virus, it can kill up to 90% of victims.
There is no cure. The virus is spread through direct contact with the blood or secretions of an infected person.
Dr. Stephan Guenther, head of the Bernhard Nocht Institute for Tropical Medicine in Hamburg, where the researcher was working, said tests so far show the scientist is healthy and free of the virus.
The peak period for an outbreak during the 21-day Ebola incubation period passed this week, he said.
"We are now on the downside," Guenther told The Associated Press, noting that with each passing day the chance of infection taking root diminishes.
It's not entirely clear the researcher was actually infected with the virus. At the time of the accident, she was wearing three layers of protective gloves, and though the needle stuck her, the plunger of the syringe was not pushed so it's not certain the virus entered her bloodstream.
That means scientists may never know if the vaccine worked or she was just lucky.